UBS downgraded Owens & Minor to Neutral from Buy with a price target of $4, down from $7. The firm cites the company’s limited earnings visibility and longer cash flow turnaround for the downgrade. UBS does not expect Owens & Minor’s EBITDA to grow in 2026 given the Kaiser loss and higher stranded costs. The company’s cash flow will not recover in the near-term given working capital constraints tied to the kitting facility, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMI:
- Owens & Minor Faces Financial Risks with P&HS Segment Asset Sale
- Owens & Minor’s Strategic Shift: Earnings Call Insights
- Owens & Minor: Navigating Transitional Challenges and Execution Risks Amidst Strategic Shift
- Owens & Minor Transitions to Home-Based Care Focus
- Owens & Minor Sells Segment, Focuses on Home Care